Should I buy or sell argenx stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares. View ARGX analyst ratings or view top-rated stocks .

What is argenx's stock price target for 2024?

21 brokerages have issued twelve-month target prices for argenx's stock. Their ARGX share price targets range from $408.00 to $641.00. On average, they anticipate the company's stock price to reach $528.16 in the next year. This suggests a possible upside of 47.4% from the stock's current price. View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts .

How have ARGX shares performed in 2024?

argenx's stock was trading at $380.43 on January 1st, 2024. Since then, ARGX stock has decreased by 5.8% and is now trading at $358.41. View the best growth stocks for 2024 here .

Are investors shorting argenx?

argenx saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,200,000 shares, a decline of 10.4% from the March 15th total of 1,340,000 shares. Based on an average daily trading volume, of 332,500 shares, the days-to-cover ratio is presently 3.6 days. View argenx's Short Interest .

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ARGX earnings forecast .

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.45. The business had revenue of $417.84 million for the quarter, compared to analysts' expectations of $378.60 million. argenx had a negative trailing twelve-month return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter last year, the business posted ($0.70) EPS.

What ETFs hold argenx's stock?

ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , American CenturyFocused Dynamic Growth ETF (FDG) , Fidelity Disruptive Medicine ETF (FMED) , iShares Biotechnology ETF (IBB) , Invesco Nasdaq Biotechnology ETF (IBBQ) , BlackRock Future Health ETF (BMED) and Invesco NASDAQ Next Gen 100 ETF (QQQJ) .

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG) , Kohl's (KSS) , AcelRx Pharmaceuticals (ACRX) , Gilead Sciences (GILD) , Neurocrine Biosciences (NBIX) , Pfizer (PFE) , CRISPR Therapeutics (CRSP) , Fate Therapeutics (FATE) , NVIDIA (NVDA) and Sarepta Therapeutics (SRPT) .

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.09%), Sumitomo Mitsui Trust Holdings Inc. (0.00%), Park Avenue Securities LLC (0.00%), Handelsinvest Investeringsforvaltning (0.00%), Steph & Co. (0.00%) and Mather Group LLC. (0.00%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARGX

argenx (ARGX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free ARGX Stock Alerts

$359.92

+1.51 (+0.42%)

(As of 11:40 AM ET)

Compare

Today's Range: $359.45
▼
$362.54
50-Day Range: $356.95
▼
$411.20
52-Week Range: $327.73
▼
$550.76

Volume: 56,500 shs
Average Volume: 316,062 shs
Market Capitalization: $21.34 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $528.16

Get argenx alerts:

argenx MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 47.4% Upside
$528.16 Price Target
Short Interest: Healthy
2.02% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.79
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.11) to $3.30 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.75 out of 5 stars

Medical Sector

210th out of 918 stocks

Biological Products, Except Diagnostic Industry

26th out of 155 stocks

4.4

Analyst's Opinion

Consensus Rating
argenx has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 14 buy ratings, 5 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
argenx has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
2.02% of the outstanding shares of argenx have been sold short.
Short Interest Ratio / Days to Cover
argenx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in argenx has recently decreased by 10.45%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
argenx does not currently pay a dividend.
Dividend Growth
argenx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARGX.

3.2

News and Social Media Coverage

News Sentiment
argenx has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for argenx this week, compared to 6 articles on an average week.
Search Interest
4 people have searched for ARGX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added argenx to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, argenx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.43% of the stock of argenx is held by insiders.
Percentage Held by Institutions
60.32% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for argenx are expected to grow in the coming year, from ($2.11) to $3.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of argenx is -69.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of argenx is -69.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
argenx has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARGX Stock News Headlines

April 18, 2024 | markets.businessinsider.com

The Analyst Verdict: argenx In The Eyes Of 12 Experts

April 17, 2024 | americanbankingnews.com

argenx SE (NASDAQ:ARGX) Receives Average Recommendation of "Moderate Buy" from Brokerages

April 19, 2024 | Stansberry Research (Ad)

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

April 16, 2024 | globenewswire.com

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

April 15, 2024 | americanbankingnews.com

argenx SE (NASDAQ:ARGX) Short Interest Down 10.4% in March

April 10, 2024 | markets.businessinsider.com

Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy

March 30, 2024 | nasdaq.com

Guru Fundamental Report for ARGX

March 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Argenx Se on Efgartigimod Progress and Regulatory Success

April 19, 2024 | Stansberry Research (Ad)

The "Smart Money" Is Ready for May 1st Are You?

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

March 29, 2024 | msn.com

Here's Why argenx SE (ARGX) Pulled Back 23% in Q4

March 29, 2024 | finance.yahoo.com

Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Argenx Se on Strong Pipeline and Market Potential

March 27, 2024 | markets.businessinsider.com

Reaffirming Buy Rating for Argenx with New Price Objective Following Vyvgart’s Approval in Japan

March 27, 2024 | markets.businessinsider.com

Key Takeaways From argenx Analyst Ratings

March 27, 2024 | finance.yahoo.com

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

March 27, 2024 | globenewswire.com

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

March 26, 2024 | globenewswire.com

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

March 26, 2024 | finanznachrichten.de

argenx SE: argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

March 26, 2024 | globenewswire.com

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

March 25, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Argenx Following Competitive Drug Trial Failure and Promising Market Prospects for Vyvgart

March 21, 2024 | markets.businessinsider.com

Buy Rating for Argenx Se Amid VYVGART’s Market Dominance and Revenue Growth Forecast

March 21, 2024 | msn.com

Argenx gains after setback to Roche/Chugai myasthenia gravis therapy

March 19, 2024 | finance.yahoo.com

Reasons to Invest in argenx (ARGX)

March 19, 2024 | investing.com

argenx NV ADR (ARGX)

March 15, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Argenx Se (ARGX), MoonLake Immunotherapeutics (MLTX)

March 8, 2024 | finanznachrichten.de

argenx SE: argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

March 7, 2024 | globenewswire.com

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

See More Headlines

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ARGX
CUSIP: N/A
CIK: 1697862
Web: www.argenx.com
Phone: (176) 303-0488
Fax: N/A
Employees: 1,148
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $528.16
High Stock Price Target: $641.00
Low Stock Price Target: $408.00
Potential Upside/Downside: +46.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-295,050,000.00
Net Margins: -23.26%
Pretax Margin: -24.00%
Return on Equity: -16.97%
Return on Assets: -15.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.75
Quick Ratio: 9.01

Sales & Book Value

Annual Sales: $1.27 billion
Price / Sales: 16.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $69.22 per share
Price / Book: 5.20

Miscellaneous

Outstanding Shares: 59,300,000
Free Float: 57,861,000
Market Cap: $21.34 billion
Optionable: Optionable
Beta: 0.65

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Timothy Van Hauwermeiren EMBA (Age 52)
M.B.A., M.Sc., CEO & Executive Director
Comp: $1.29M
Mr. Karl Gubitz (Age 54)
Chief Financial Officer
Comp: $843.26k
Ms. Karen Massey (Age 45)
Chief Operating Officer
Comp: $1.42M
Mr. Filip Borgions
VP & Global Head of Technical Operations
Mr. Peter Ulrichts (Age 44)
Chief Scientific Officer
Ms. Beth DelGiacco
VP and Global Head of Corporate Communications & Investor Relations
Ms. Malini Moorthy (Age 54)
General Counsel
Mr. Arjen Lemmen M.Sc. (Age 39)
Vice President of Corporate Development & Strategy
Mr. Marc Schorpion (Age 65)
Global Head of Human Resources
Ms. Andria Wilk (Age 50)
Global Head of Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy argenx Stock? ARGX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in argenx SE:

Positive clinical trial results for Vyvgart Hytrulo showing a 61% decline in the risk of relapse, indicating strong potential for revenue growth.
Market capitalization of $29.30 billion despite not posting a profit, showcasing investor confidence in the company's drug pipeline.
Potential acquisition target by larger pharmaceutical firms due to its robust drug pipeline focusing on severe autoimmune diseases.
Vyvgart Hytrulo's revenue generation potential and regulatory approval for treating various conditions could lead to significant cash flow gains.
High valuations in the biotechnology sector due to innovative treatments, making argenx SE an attractive investment option.

Cons

Investors should be bearish about investing in argenx SE for these reasons:

Company has never posted a profit, indicating potential financial risks for investors.
Reliance on a single revenue-generating product, Vyvgart Hytrulo, may pose concentration risk if the product faces challenges.
Uncertainty in the biotech industry regarding regulatory approvals and market acceptance of new treatments, leading to investment volatility.
Potential competition from other biopharmaceutical companies developing similar therapies, impacting market share and revenue growth.
Investors need to carefully assess the risks associated with investing in a company with a focus on autoimmune diseases and unproven profitability.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.
What is argenx's stock price target for 2024?: 21 brokerages have issued twelve-month target prices for argenx's stock. Their ARGX share price targets range from $408.00 to $641.00. On average, they anticipate the company's stock price to reach $528.16 in the next year. This suggests a possible upside of 47.4% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.
How have ARGX shares performed in 2024?: argenx's stock was trading at $380.43 on January 1st, 2024. Since then, ARGX stock has decreased by 5.8% and is now trading at $358.41.
View the best growth stocks for 2024 here.
Are investors shorting argenx?: argenx saw a decline in short interest in March. As of March 31st, there was short interest totaling 1,200,000 shares, a decline of 10.4% from the March 15th total of 1,340,000 shares. Based on an average daily trading volume, of 332,500 shares, the days-to-cover ratio is presently 3.6 days.
View argenx's Short Interest.
When is argenx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ARGX earnings forecast.
How were argenx's earnings last quarter?: argenx SE (NASDAQ:ARGX) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.45. The business had revenue of $417.84 million for the quarter, compared to analysts' expectations of $378.60 million. argenx had a negative trailing twelve-month return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter last year, the business posted ($0.70) EPS.

What ETFs hold argenx's stock?: ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), American CenturyFocused Dynamic Growth ETF (FDG), Fidelity Disruptive Medicine ETF (FMED), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), BlackRock Future Health ETF (BMED) and Invesco NASDAQ Next Gen 100 ETF (QQQJ).
What other stocks do shareholders of argenx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).
When did argenx IPO?: argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are argenx's major shareholders?: argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.09%), Sumitomo Mitsui Trust Holdings Inc. (0.00%), Park Avenue Securities LLC (0.00%), Handelsinvest Investeringsforvaltning (0.00%), Steph & Co. (0.00%) and Mather Group LLC. (0.00%).
How do I buy shares of argenx?: Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

argenx (ARGX) Stock Price, News & Analysis

argenx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About argenx Stock (NASDAQ:ARGX)

ARGX Stock Price History

ARGX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

Should I Buy argenx Stock? ARGX Pros and Cons Explained

Pros

Cons

ARGX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™